United Therapeutics (UTHR) Total Liabilities (2009 - 2026)

United Therapeutics has disclosed Total Liabilities across 18 years of filings, most recently posting $819.8 million for Q2 2026.

• In Q2 2026, Total Liabilities rose 11.63% year-over-year to $819.8 million; the TTM figure through Jun 2026 stood at $819.8 million (up 11.63% YoY), while the FY2025 annual figure was $783.8 million, down 14.8% from the prior year.
• Total Liabilities came in at $819.8 million for Q2 2026 at United Therapeutics, up from $813.1 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $1.3 billion in Q3 2023 to a low of $734.4 million in Q2 2025.
• Average Total Liabilities over 5 years is $1.0 billion, with a median of $1.1 billion recorded in 2024.
• Year-over-year, Total Liabilities retreated 28.42% in 2025 and climbed 11.63% in 2026.
• Over 5 years, Total Liabilities stood at $1.2 billion in 2022, then retreated by 5.26% to $1.2 billion in 2023, then declined by 22.18% to $920.0 million in 2024, then retreated by 14.8% to $783.8 million in 2025, then grew by 4.59% to $819.8 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $819.8 million in Q2 2026, $813.1 million in Q1 2026, and $783.8 million in Q4 2025.